65,437 trials
Heart Failure
Primary: Left Ventricular End-systolic Volume (LVESV) — -15; -19; -21 ml — p=.66
Head and Neck Cancer
Primary: Response Probability (Confirmed Complete and Partial Responses) — 0; 2; 38 participants
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) With Response as Assessed by the Investigator — 31 participants
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Renal Plasma Flow (RPF) After a Single Dose of Aliskiren or Irbesartan — 37.18; 35.88 mL/min/1.73m^2
Refractive Error
Primary: Phase 3: Ocular Comfort, Lens Age 1 Day, Hour 1 — 76; 88 Units on a scale
Parkinsonian Syndromes
Primary: Changes That the Doctor Made in the Clinical Management of Subjects Based Upon the Impact of the Imaging Product. — 33; 28; 19; 11 Number of changes in clinical management
Head and Neck Neoplasms · Pheochromocytoma · Colorectal Neoplasms
Primary: Response Rate — 0; 0; 26; 11 Participants
Asthma
Primary: Adverse Events — 14; 24 adverse events
Papulopustular Rosacea
Primary: Nominal Change From Baseline in Inflammatory Lesion (IL) Count (Sum of Papules and Pustules) at Week 2 (LOCF: Last Observation Carried Forward) — -10.5; -9.4…
Tumors
Primary: Proportion of Patients Requiring Temporary (>1 Day) or Permanent Withdrawal of AZD2171 Prior to Progression and Within 12 Weeks of First Dose of AZD2171 — 12; 19; 20; 24…
Acute Coronary Syndrome
Primary: Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events (Primary Safety) — 36; 17; 109; 43 Patients
Prostate Cancer
Primary: Safety and Tolerability of Custirsen (OGX-011) in Combination With Either Docetaxel/Prednisone or Mitoxantrone/Prednisone as Second-line Chemotherapy. — 26; 26; 13; 4…
Type 1 Diabetes
Primary: The Area Under the Curve (AUC) of Plasma Glucose (PG) Concentrations During the 5-hour Postprandial Period (AUC-PG0-5 h). — 724.6; 668.8 mg*h/dl
Neoplasms, Breast
Primary: Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee — 2; 12; 58; 54…
Nausea and Vomiting, Postoperative
Primary: Incidence of Nausea — 46; 54 percentage of participants